CN108473583A - 用于治疗葡萄膜炎和黄斑水肿的包含il6r抗体的组合物及其使用方法 - Google Patents

用于治疗葡萄膜炎和黄斑水肿的包含il6r抗体的组合物及其使用方法 Download PDF

Info

Publication number
CN108473583A
CN108473583A CN201680077216.5A CN201680077216A CN108473583A CN 108473583 A CN108473583 A CN 108473583A CN 201680077216 A CN201680077216 A CN 201680077216A CN 108473583 A CN108473583 A CN 108473583A
Authority
CN
China
Prior art keywords
composition
subject
uveitis
weeks
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680077216.5A
Other languages
English (en)
Chinese (zh)
Inventor
P·A·斯立德拉桑达母
R·巴嘎格
K·W·楚
V·考普迪特真蒂
K·A·埃里克森
D·玛丽-米妮亚德
R·瓦罗纳
R·L·维蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Drugmaker Of Regenerating
Sanofi SA
Original Assignee
First Drugmaker Of Regenerating
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Drugmaker Of Regenerating, Sanofi SA filed Critical First Drugmaker Of Regenerating
Publication of CN108473583A publication Critical patent/CN108473583A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680077216.5A 2015-11-03 2016-11-03 用于治疗葡萄膜炎和黄斑水肿的包含il6r抗体的组合物及其使用方法 Pending CN108473583A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562250269P 2015-11-03 2015-11-03
US62/250,269 2015-11-03
EP16306166 2016-09-14
EP16306166.6 2016-09-14
US201662408391P 2016-10-14 2016-10-14
US62/408,391 2016-10-14
PCT/US2016/060344 WO2017079443A1 (en) 2015-11-03 2016-11-03 Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same

Publications (1)

Publication Number Publication Date
CN108473583A true CN108473583A (zh) 2018-08-31

Family

ID=57018106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680077216.5A Pending CN108473583A (zh) 2015-11-03 2016-11-03 用于治疗葡萄膜炎和黄斑水肿的包含il6r抗体的组合物及其使用方法

Country Status (13)

Country Link
US (2) US10968278B2 (enExample)
EP (1) EP3371224A1 (enExample)
JP (4) JP7272794B2 (enExample)
KR (1) KR20180073680A (enExample)
CN (1) CN108473583A (enExample)
AU (2) AU2016348418B8 (enExample)
BR (1) BR112018008900A8 (enExample)
CA (1) CA3003874A1 (enExample)
IL (1) IL319993A (enExample)
MX (2) MX2018005589A (enExample)
SG (1) SG11201803654TA (enExample)
TW (3) TW202339795A (enExample)
WO (1) WO2017079443A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JP7272794B2 (ja) * 2015-11-03 2023-05-12 サノフィ・バイオテクノロジー ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法
TWI868074B (zh) 2018-08-29 2025-01-01 美商再生元醫藥公司 用來治療患有類風濕性關節炎之個體的方法及組成物
EP3917618A1 (en) 2019-01-31 2021-12-08 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
MA56116A (fr) 2019-06-04 2022-04-13 Stefano Fiore Compositions et procédés de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoïde
EP3986481A2 (en) 2019-06-20 2022-04-27 Takeda Pharmaceutical Company Limited Method of treatment with viral-based gene therapy
AU2021371307A1 (en) * 2020-10-28 2023-06-01 Regenxbio, Inc. VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
TW202426494A (zh) * 2022-10-24 2024-07-01 瑞士商赫孚孟拉羅股份公司 預測對ｉｌ－６拮抗劑的反應

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140348A2 (en) * 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
CN104105505A (zh) * 2011-10-11 2014-10-15 赛诺菲 用于治疗类风湿性关节炎的组合物及其使用方法
CN104903349A (zh) * 2012-11-08 2015-09-09 十一生物治疗股份有限公司 Il-6拮抗剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205553B (enExample) 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
CA2201781C (en) 1994-10-07 2010-01-12 Tadamitsu Kishimoto Chronic rheumatoid arthritis therapy containing il-6 antagonist as effective component
PL187733B1 (pl) 1996-02-26 2004-09-30 Advanced Res & Tech Inst Zastosowanie inhibitora anhydrazy węglanowej
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
MXPA06012915A (es) 2004-05-06 2007-03-01 Gov Health & Human Serv Metodos y composiciones para el tratamiento de uveitis.
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
EA201201526A1 (ru) 2010-05-07 2013-06-28 Ксома Текнолоджи Лтд. Способы лечения состояний, связанных с il-1b
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
MX377190B (es) 2013-11-22 2025-03-07 Sanofi Biotechnology Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
JP7272794B2 (ja) * 2015-11-03 2023-05-12 サノフィ・バイオテクノロジー ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140348A2 (en) * 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
CN104105505A (zh) * 2011-10-11 2014-10-15 赛诺菲 用于治疗类风湿性关节炎的组合物及其使用方法
CN104903349A (zh) * 2012-11-08 2015-09-09 十一生物治疗股份有限公司 Il-6拮抗剂及其应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALFREDO ADÁN等，: "Tocilizumab treatment for refractory uveitis-related", 《GRAEFES ARCH CLIN EXP OPHTHALMOL》 *
LEYRE RIANCHO-ZARRABEITIA等: "Efficacy of Tocilizumab in Patients with Uveitis Refractory to Other Biologic Drugs: A Multicenter Study on 31 Cases", 《2014 ACR/ARHP ANNUAL MEETING》 *
MARINA MESQUIDA等: "Long-Term Effects of Tocilizumab Therapy for Refractory Uveitis-Related Macular Edema", 《OPHTHALMOLOGY》 *
PHOEBE LIN: "Targeting interleukin-6 for noninfectious uveitis", 《CLINICAL OPHTHALMOLOGY》 *
QUAN DONG NGUYEN等，: "The SATURN Study (SARIL-NIU): Sarilumabfor the Treatment of Posterior SegmentNon-Infectious Uveitis (NIU)", 《INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE》 *
ROBERT J BARRY等，: "Pharmacotherapy for uveitis: current management and emerging therapy", 《CLINICAL OPHTHALMOLOGY》 *
SPONSOR:SANOFI: "Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis(SARILNIUSATURN)", 《CLINICALTRIALS.GOV》 *
艾华等: "视网膜中央静脉阻塞黄斑水肿时VEGF和IL-6在前房和玻璃体腔的表达", 《细胞与分子免疫学杂质》 *

Also Published As

Publication number Publication date
TWI729022B (zh) 2021-06-01
MX2022011972A (es) 2022-10-20
EP3371224A1 (en) 2018-09-12
TW201729828A (zh) 2017-09-01
JP2018532804A (ja) 2018-11-08
JP2021193120A (ja) 2021-12-23
US20170166646A1 (en) 2017-06-15
MX2018005589A (es) 2018-11-09
KR20180073680A (ko) 2018-07-02
BR112018008900A2 (pt) 2018-11-06
US20210301027A1 (en) 2021-09-30
CA3003874A1 (en) 2017-05-11
AU2016348418B8 (en) 2023-10-19
AU2023233110A1 (en) 2023-10-05
TWI786636B (zh) 2022-12-11
JP7272794B2 (ja) 2023-05-12
JP2023062062A (ja) 2023-05-02
WO2017079443A8 (en) 2017-07-06
WO2017079443A1 (en) 2017-05-11
TW202339795A (zh) 2023-10-16
BR112018008900A8 (pt) 2019-02-26
TW202138001A (zh) 2021-10-16
US10968278B2 (en) 2021-04-06
JP2025020227A (ja) 2025-02-12
JP7581399B2 (ja) 2024-11-12
AU2016348418B2 (en) 2023-10-12
AU2016348418A1 (en) 2018-06-21
IL319993A (en) 2025-06-01
AU2016348418A8 (en) 2023-10-19
SG11201803654TA (en) 2018-05-30

Similar Documents

Publication Publication Date Title
JP7581399B2 (ja) ブドウ膜炎および黄斑浮腫の処置のためのｉｌ６ｒ抗体を含む組成物およびそれを使用する方法
CA3079946A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
TR201802387T4 (tr) Romatoid artritin tedavisine yönelik bileşimler ve bunun kullanımının yöntemleri.
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
KR20220093008A (ko) 손발톱 및 두피 건선의 치료 방법
JP2017528465A (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用
JP2025134086A (ja) 関節リウマチを有する対象における疼痛を治療するための組成物および方法
KR20210122810A (ko) 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
EP3833687A1 (en) A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
US20230192871A1 (en) Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis
RU2747193C2 (ru) Композиции, содержащие антитела к il6r, для лечения увеита и макулярного отека, и способы их применения
WO2022234440A1 (en) Treatment for lupus nephritis using anti-baffr antibodies
KR102628314B1 (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
RU2853717C1 (ru) Композиции и способы лечения невоспалительной боли у субъектов с ревматоидным артритом

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180831